Roth Capital's analyst, Boobalan Pachaiyappan, has revised the price target for Cingulate (CING, Financial), reducing it from $12 to $11, while maintaining a Buy rating following the company's first-quarter results. The adjustment comes after ongoing discussions with Cingulate's management, which have reinforced the analyst's confidence in the forthcoming application for CTx-1301. This filing is anticipated by the third quarter, with expectations for the drug's FDA approval by the fourth quarter of 2026 and a subsequent market launch in the first half of 2027.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cingulate Inc (CING, Financial) is $29.00 with a high estimate of $60.00 and a low estimate of $8.00. The average target implies an upside of 659.16% from the current price of $3.82. More detailed estimate data can be found on the Cingulate Inc (CING) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Cingulate Inc's (CING, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
